Drugs / HS-10384
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06122181 | Nov 2023 → Jun 2024 | — | Hansoh BioMedical R&D Company | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06393673 | May 2024 → Jun 2025 | — | Hansoh BioMedical R&D Company | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10384 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06393673 ↗ |
| Route | Oral | “Multiple dosing of HS-10384 orally in a fasting state” NCT06122181 ↗ |